Chromadex Corp. Hits New 52-Week Low at $4.74 Amid Market Volatility

Chromadex Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 4.74 on February 23, 2026. This marks a significant decline from its 52-week high of USD 14.69, highlighting the volatility in its stock performance over the past year. Despite this downturn, Chromadex Corp. has shown a notable one-year performance increase of 62.66%, significantly outperforming the S&P 500, which recorded a gain of 12.95% during the same period. The company's market capitalization stands at USD 388 million, reflecting its microcap status within the industry. Financial metrics indicate a price-to-earnings (P/E) ratio of 30.00, while the return on equity is reported at 28.91%, suggesting effective management of shareholder equity. Additionally, Chromadex Corp. maintains a price-to-book ratio of 5.49, although it does not offer a dividend yield. The company's debt-to-equity ratio is noted at -0.90, indicating a unique financial structure. Overall, the recent price movement underscores the dynamic nature of Chromadex Corp.'s market position.